BTC Health has transformed its decade-long license agreement with Arna Pharma into an indefinite partnership, gaining royalties from Singapore and Malaysia sales and first rights to new pharmaceutical products in Australia and New Zealand.
Recce Pharmaceuticals has gained key regulatory and ethics approvals for its Phase 3 clinical trial in Indonesia and completed patient dosing for its Phase II trial, while securing a substantial A$6.75 million R&D tax rebate to bolster its financial position.